salmeterol   Click here for help

GtoPdb Ligand ID: 559

Synonyms: GR 33343X | Serevent®
Approved drug Immunopharmacology Ligand
salmeterol is an approved drug (FDA (1994), EMA (2016))
Compound class: Synthetic organic
Comment: Marketed formulations may contain salmeterol xinafoate (PubChem CID 56801).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: salmeterol

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 4
Rotatable bonds 16
Topological polar surface area 81.95
Molecular weight 415.27
XLogP 4.18
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O
Isomeric SMILES OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O
InChI InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2
No information available.
Summary of Clinical Use Click here for help
As a monotherapy FDA and EMA approvals are for as the use of salmeterol xinafoate. Salmeterol xinafoate is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is also approved in a fixed-dose inhalation powder formulation with the long-acting β2-adrenergic agonist fluticasone propionate (e.g. AirDuo RespiClickTM or Aerivio SpiromaxTM) for the treatment of severe asthma and COPD.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Causes stimulation of β2 adrenoceptors in the lung leading to relaxation of bronchial smooth muscle, bronchodilation and increased bronchial airflow.
External links Click here for help